Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Eastern Cooperative Oncology Group
Colorado State University
Zagazig University
University Health Network, Toronto
Essen Biotech
Brigham and Women's Hospital
St. Jude Children's Research Hospital
Institut BergoniƩ
Duke University
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
ITM Solucin GmbH
University of Salamanca
AC Camargo Cancer Center
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Incyte Corporation
Immunitas Therapeutics
M.D. Anderson Cancer Center
Arab American University (Palestine)
National Cancer Institute (NCI)
Washington University School of Medicine
Incyte Corporation
Trishula Therapeutics, Inc.
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Massachusetts General Hospital
University Medical Center Groningen
Cedars-Sinai Medical Center
National Institutes of Health Clinical Center (CC)
Eisai Inc.
Haukeland University Hospital
Memorial Sloan Kettering Cancer Center
Stingthera, Inc.
Celgene
City of Hope Medical Center
Eastern Cooperative Oncology Group
Fate Therapeutics
Genzada Pharmaceuticals USA, Inc.
ImmVira Pharma Co. Ltd
Blue Note Therapeutics
Eutilex
Novartis
Incyte Corporation
University Health Network, Toronto
AstraZeneca